SK287791B6 - Použitie dlhého pentraxin PTX3 alebo jeho funkčných derivátov alebo domén na prípravu liečiva - Google Patents

Použitie dlhého pentraxin PTX3 alebo jeho funkčných derivátov alebo domén na prípravu liečiva Download PDF

Info

Publication number
SK287791B6
SK287791B6 SK562-2003A SK5622003A SK287791B6 SK 287791 B6 SK287791 B6 SK 287791B6 SK 5622003 A SK5622003 A SK 5622003A SK 287791 B6 SK287791 B6 SK 287791B6
Authority
SK
Slovakia
Prior art keywords
ptx3
fgf
diseases caused
cells
tumor
Prior art date
Application number
SK562-2003A
Other languages
English (en)
Slovak (sk)
Other versions
SK5622003A3 (en
Inventor
Alberto Mantovani
Barbara Botazzi
Marco Presta
Marco Rusnati
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Publication of SK5622003A3 publication Critical patent/SK5622003A3/sk
Publication of SK287791B6 publication Critical patent/SK287791B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
SK562-2003A 2000-11-08 2001-11-08 Použitie dlhého pentraxin PTX3 alebo jeho funkčných derivátov alebo domén na prípravu liečiva SK287791B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2000RM000578A IT1317930B1 (it) 2000-11-08 2000-11-08 Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione
PCT/IT2001/000563 WO2002038169A1 (en) 2000-11-08 2001-11-08 Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2

Publications (2)

Publication Number Publication Date
SK5622003A3 SK5622003A3 (en) 2003-10-07
SK287791B6 true SK287791B6 (sk) 2011-10-04

Family

ID=11454983

Family Applications (1)

Application Number Title Priority Date Filing Date
SK562-2003A SK287791B6 (sk) 2000-11-08 2001-11-08 Použitie dlhého pentraxin PTX3 alebo jeho funkčných derivátov alebo domén na prípravu liečiva

Country Status (22)

Country Link
US (1) US7858577B2 (xx)
EP (1) EP1331940B1 (xx)
JP (1) JP4167061B2 (xx)
KR (1) KR100822357B1 (xx)
CN (1) CN1304047C (xx)
AT (1) ATE322906T1 (xx)
AU (2) AU2002222513B8 (xx)
BR (1) BR0115190A (xx)
CA (1) CA2428176C (xx)
CY (1) CY1106092T1 (xx)
CZ (1) CZ299673B6 (xx)
DE (1) DE60118769T2 (xx)
DK (1) DK1331940T3 (xx)
ES (1) ES2261515T3 (xx)
HK (1) HK1061209A1 (xx)
HU (1) HU229100B1 (xx)
IT (1) IT1317930B1 (xx)
MX (1) MXPA03004005A (xx)
PL (1) PL205925B1 (xx)
PT (1) PT1331940E (xx)
SK (1) SK287791B6 (xx)
WO (1) WO2002038169A1 (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
ITRM20020109A1 (it) * 2002-02-28 2003-08-28 Sigma Tau Ind Farmaceuti Derivati funzionali della pentraxina lunga ptx3 per preparare un vaccino autologo per la cura dei tumori.
ITRM20020191A1 (it) * 2002-04-08 2003-10-08 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie tumorali associate ad una alterata att
ITRM20030596A1 (it) * 2003-12-23 2005-06-24 Sigma Tau Ind Farmaceuti Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.
WO2005080981A1 (ja) * 2004-02-25 2005-09-01 Perseus Proteomics Inc. 血管障害の程度の判定方法
ITRM20040489A1 (it) 2004-10-08 2005-01-08 Sigma Tau Ind Farmaceuti Pentraxina lunga ptx3 deglicosilata o desialidata.
JP5427415B2 (ja) * 2006-01-24 2014-02-26 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ Ｆｇｆ２結合性ペプチドおよびそれらの使用
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
ES2389452T3 (es) 2006-05-02 2012-10-26 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Uso de timosina 1, sola o en combinación con PTX3 o ganciclovir, para el tratamiento de infección por citomegalovirus
JP6236633B2 (ja) * 2012-06-22 2017-11-29 国立大学法人 東京大学 全身性炎症反応症候群の治療又は予防剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1235392A (en) * 1991-01-14 1992-08-17 New York University Cytokine-induced protein, tsg-14, dna coding therefor and uses thereof
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,

Also Published As

Publication number Publication date
CA2428176A1 (en) 2002-05-16
MXPA03004005A (es) 2004-05-05
EP1331940B1 (en) 2006-04-12
AU2002222513B8 (en) 2006-11-23
ATE322906T1 (de) 2006-04-15
BR0115190A (pt) 2004-02-03
CZ20031179A3 (cs) 2003-11-12
HU229100B1 (en) 2013-07-29
KR20030061396A (ko) 2003-07-18
IT1317930B1 (it) 2003-07-15
ITRM20000578A1 (it) 2002-05-08
CZ299673B6 (cs) 2008-10-15
PL205925B1 (pl) 2010-06-30
AU2251302A (en) 2002-05-21
HUP0400541A3 (en) 2006-01-30
ES2261515T3 (es) 2006-11-16
JP2004513151A (ja) 2004-04-30
EP1331940A1 (en) 2003-08-06
CN1304047C (zh) 2007-03-14
JP4167061B2 (ja) 2008-10-15
CN1473050A (zh) 2004-02-04
HUP0400541A2 (hu) 2004-05-28
CY1106092T1 (el) 2011-06-08
PL365292A1 (en) 2004-12-27
PT1331940E (pt) 2006-07-31
DK1331940T3 (da) 2006-08-14
CA2428176C (en) 2013-02-05
DE60118769D1 (de) 2006-05-24
KR100822357B1 (ko) 2008-04-16
SK5622003A3 (en) 2003-10-07
WO2002038169A1 (en) 2002-05-16
US7858577B2 (en) 2010-12-28
DE60118769T2 (de) 2007-01-04
HK1061209A1 (en) 2004-09-10
US20040023879A1 (en) 2004-02-05
AU2002222513B2 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
Presta et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis
Reilly et al. Regulation of astrocyte GFAP expression by TGF‐β1 and FGF‐2
Albini et al. The angiogenesis induced by HIV–1 Tat protein is mediated by the Flk–1/KDR receptor on vascular endothelial cells
Nyberg et al. Endogenous inhibitors of angiogenesis
JP3854307B2 (ja) 細胞外マトリックスの蓄積を防止するためのトランスフォーミング増殖因子βの阻害
Keshamouni et al. PPAR-γ activation inhibits angiogenesis by blocking ELR+ CXC chemokine production in non-small cell lung cancer
Shu et al. Ablation of perlecan domain 1 heparan sulfate reduces progressive cartilage degradation, synovitis, and osteophyte size in a preclinical model of posttraumatic osteoarthritis
JP4993834B2 (ja) 細胞増殖および血管形成の調節物質、その使用方法および特定方法
US5744492A (en) Method for inhibiting angiogenesis
SK287791B6 (sk) Použitie dlhého pentraxin PTX3 alebo jeho funkčných derivátov alebo domén na prípravu liečiva
AU2002222513A1 (en) Use of the long pentraxin PTX3 for the treatment of diseases caused by an altered activation of the growth factor FGF-2
Leenders Targetting VEGF in anti‐angiogenic and anti‐tumour therapy: Where are we now?
Hatzi et al. N‐myc oncogene overexpression down‐regulates leukemia inhibitory factor in neuroblastoma
Bond et al. Interaction of angiogenesis inhibitor TNP-470 with basic fibroblast growth factor receptors
US20050043230A1 (en) Use of long pentraxin ptx3 for the treatment of fgf-8 mediated tumour diseases
Shestenko et al. Angiogenin and its functions in angiogenesis
Sirén et al. α-Trinositol inhibits FGF-stimulated growth of smooth muscle and breast cancer cells
JACKSON et al. Angiogenesis and the Endothelial Cell Cycle
US20020182587A1 (en) Methods and compositions for the treatment and prevention of smooth muscle cell proliferation
Kalluri et al. Matrix-Associated Endogenous Inhibitors of Angiogenesis
Guo CD105 expression and its effects on TGF-β signalling, angiogenesis and cell behaviour
Lin CCN3-induced activities in cutaneous wound healing, angiogenesis, and proliferative restenosis
KR20180016076A (ko) Ptp4a1 단백질 또는 이를 암호화 하는 폴리뉴클레오티드를 유효성분으로 함유하는 혈관염증질환 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20161108